Eli Lilly's (LLY) sofetabart mipitecan receives US FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
Importance
Level 1
#ELI LILLY & CO#LLY.US#FDA#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#US EQUITIES